COMPOUNDS FOR
BORON NEUTRON CAPTURE THERAPY
Boron neutron capture therapy (BNCT) is a bi-modal anti-cancer therapy comprising a 10-boron agent and neutrons. The 10-boron agent is administered intravenously to the patient. The 10-boron agent is taken up by the tumor cells. The patient is irradiated with neutrons.
Upon neutron capture, the 10-boron nucleus decays to 7-lithium and 4-helium nuclei of high energy, which effectively destroy cancer cells within the range of a cell diameter. Both, 10-boron agents and neutrons applied for BNCT are virtually non-toxic. Moreover, decay products of the boron nucleus are characterized by short half-life times and ranges resulting in high-precision tumor cell eradication.
Advantages
• Minimal clinical side-effects
• High efficacy in tumor patients even for late-stage tumors
PHARMACEUTICALS FOR BNCT
Products
4-Borono-L-phenylalanine
Tumor target: L-type amino acid transporter 1 (LAT1)
LAT1 overexpression in many tumors like head and neck cancer, basal cell carcinoma, melanoma, glioblastoma, lung cancer, breast cancer, and adenocarcinoma.
Services
BNCT Pharmaceutical Development:
- Conjugates
- Clusters & Nanoparticles for higher tumor specificity and higher treatment sensitivity
BNCT Pharmaceutical Formulation:
- Boronophenylalanine complexes, lipid nanoparticle formulations for improved bioavailability and pharmacokinetics / dynamics
WellMarin-BPA is a boronophenylalanine complex offering high solubility in aqueous solutions, high stability and high tumor cell uptake. It offers higher tumor specificity compared to non-complexed boronophenylalanine.
WellMarin-TumorDelivery-10B is a family of 10-boron drug delivery systems that specifically target individual tumor entities while healthy cells are spared.
This results in unmet specificity of the Boron-Neutron-Capture Therapy for minimal side effects. The system offers the opportunity to target specifically different types and subtypes of the tumor and even individual patients’ tumor signatures. Thus, tailored 10-boron cancer therapies can be provided.
Furthermore, the WellMarin 10-boron drug delivery systems offer the possibility to transport high amounts of 10-boron into the tumor cell and especially to the nucleus where 10-boron-initiated tumor cell eradication is most efficient. High 10-boron tumor cell load optimizes Boron-Neutron-Capture Therapy with respect to efficacy, sustainability, and patients’ quality of life. An additional effect is that the procedure is gentler for the patient.
Another aspect of the WellMarin 10-boron drug delivery systems is to protect the API during the transportation process.
Last but not least the WellMarin 10-boron drug delivery systems promote transportation of the API trough barriers in the human body.
WellMarin-TumorEntry-10B is a family of 10-boron derivatives designed to enter tumor cells with specific signatures according to patients’ tumor characterization.
WellMarin-TumorGene-10B is a family of Boron-Neutron-Capture + Gene combination therapies for effective tumor treatment and eradication.
WellMarin-TumorVac-10B is a family of Boron-Neutron-Capture + Tumor Vaccination combination therapies for effective tumor treatment and cure.
WellMarin-VIS-10B is a family of 10-boron derivatives to be used in imaging procedure applying 10-boron drugs.